Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
Portfolio Pulse from Vandana Singh
The FDA's Oncologic Drugs Advisory Committee will meet to discuss potential restrictions on PD-1 drugs for stomach cancer, focusing on PD-L1 expression as a biomarker. This review affects Merck's Keytruda, Bristol Myers' Opdivo and Yervoy, and BeiGene's Tevimbra.
August 23, 2024 | 6:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BeiGene's Tevimbra, recently approved for esophageal cancer, is under FDA review for potential restrictions based on PD-L1 expression, which could impact its future market.
Tevimbra's recent approval could be affected by the FDA's review focusing on PD-L1 expression, potentially limiting its use and impacting its market.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Bristol Myers' Opdivo and Yervoy are under FDA review for stomach cancer treatment, with potential restrictions based on PD-L1 expression. This could affect their market presence.
The FDA's focus on PD-L1 expression as a biomarker could lead to restricted use of Opdivo and Yervoy, affecting their market if approvals are limited.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Merck's Keytruda is under FDA review for its use in stomach cancer, with potential restrictions based on PD-L1 expression. This could impact its market if approvals are limited.
The FDA review could lead to restrictions on Keytruda's use in stomach cancer, potentially reducing its market if approvals are limited based on PD-L1 expression.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90